Sanara MedTech Inc.
NASDAQ:SMTIMedical - Instruments & Supplies
+$0.73 today
- Market cap
- $300.55M
- Beta
- 1.19
- P/E (TTM)
- -5.7
- EPS (TTM)
- -$3.86
Volume 0.07M
Average 0.06M
SMTI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Sanara MedTech Inc.NASDAQ: SMTI
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $759.59K fell 31.8% year over year, behind the -13.4% change in trailing-twelve-month research & development. Sequentially, it fell 62.7% from the prior quarter. Over 3 fiscal years it compounded at +14.6% a year.
Context
- Research & development amounted to 4.9% of revenue in FY2025, down 1.7 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -31.8% toward the trailing-twelve-month pace of -13.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 5.07M USD
- Year-over-year change
- -11.1%
- 4-year CAGR
- +73.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.07M | -11.1% |
| FY2024 | 2024-12-31 | 5.7M | +38.0% |
| FY2023 | 2023-12-31 | 4.13M | +22.7% |
| FY2022 | 2022-12-31 | 3.37M | +502.7% |
| FY2021 | 2021-12-31 | 558.7K | — |
Research & Development vs competitors
How SMTI compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -13.4% is the 7th highest of 9, against a peer median of +2.5%.
- Research & development amounts to 4.7% of revenue for SMTI, versus a peer median of 9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $143.25M USD | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $39.88M USD | +24.6% | +1.7% | 11.5% | |
| LTM Jun 2026 | $38.17M USD | +9.5% | +6.9% | 5.0% | |
| LTM Mar 2026 | $12.72M USD | -28.5% | -13.9% | 16.0% | |
| LTM Mar 2026 | $9.43M USD | -4.4% | -3.9% | 30.2% | |
| LTM Mar 2026 | $7.53M USD | -25.4% | +35.2% | 3.4% | |
| LTM Mar 2026 | $6.52M USD | +16.5% | -14.1% | 9.5% | |
| LTM Mar 2026 | $5.08M USD | -13.4% | +14.6% | 4.7% | |
| LTM Mar 2026 | $2.8M USD | -10.1% | +3.8% | 1.0% | |
| LTM Apr 2026 | CA$0 CAD | — | — | 0.0% | |
| Peer median (excluding SMTI) | — | +2.5% | +2.8% | 9.5% | |
Competitors are the stored peer set for SMTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 24.14M | 45.84M | 64.99M | 86.67M | 103.12M |
| Cost of Revenue | 2.31M | 6.36M | 7.85M | 8.14M | 10.18M |
| Gross Profit | 21.83M | 39.48M | 57.14M | 78.53M | 92.94M |
| Gross Margin | 90.4% | 86.1% | 87.9% | 90.6% | 90.1% |
| Research & Development | 558.7K | 3.37M | 4.13M | 5.7M | 5.07M |
| Selling, General & Admin | 28.05M | 45.98M | 56.99M | 76.56M | 78.72M |
| Operating Expenses | 29.21M | 52M | 61.35M | 85.25M | 83.79M |
| Depreciation & Amortization | 771.93K | 2.37M | 3.68M | 4.92M | 2.66M |
| EBITDA | (7.22M) | (11.57M) | (289.1K) | (1.86M) | 9.03M |
| EBITDA Margin | -29.9% | -25.2% | -0.4% | -2.1% | 8.8% |
| Operating Income | (7.38M) | (12.52M) | (4.22M) | (6.72M) | 9.15M |
| Operating Margin | -30.6% | -27.3% | -6.5% | -7.7% | 8.9% |
| Interest Income | 0 | 284.75K | 0 | 21.98K | 3.67K |
| Interest Expense | 711 | 284.75K | 475.78K | 3.13M | 6.76M |
| Other Income / Expenses | (617.64K) | (1.42M) | (224.75K) | (3.2M) | (9.54M) |
| Income Before Tax | (7.99M) | (13.94M) | (4.44M) | (9.91M) | (393.12K) |
| Pre-Tax Margin | -33.1% | -30.4% | -6.8% | -11.4% | -0.4% |
| Income Tax Expense | 0 | (5.84M) | 0 | 0 | 0 |
| Net Income | (7.92M) | (7.94M) | (4.3M) | (9.66M) | (37.56M) |
| Net Margin | -32.8% | -17.3% | -6.6% | -11.2% | -36.4% |
| EPS (Basic) | (1.08) | (1.00) | (0.52) | (1.14) | (4.36) |
| EPS (Diluted) | (1.08) | (1.00) | (0.52) | (1.14) | (4.36) |
| Weighted Avg Shares | 7.34M | 7.91M | 8.28M | 8.48M | 8.62M |
| Weighted Avg Shares (Diluted) | 7.34M | 7.91M | 8.28M | 8.48M | 8.62M |
Sanara MedTech Inc.
NASDAQ:SMTI
Intrinsic Alpha fair value
Locked
Current Price
$32.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.